Last reviewed · How we verify
Bacillus subtilis
Bacillus subtilis, marketed by DreamTec Research Limited, is positioned in the treatment of skin and lung conditions. The drug's key strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the key composition patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Bacillus subtilis |
|---|---|
| Sponsor | DreamTec Research Limited |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
- Skin and Lung Conditions
- Stomach and Intestinal Imbalance
- Rheumatism Symptoms
- Skin Allergies
- Other Internal Conditions
Common side effects
Key clinical trials
- Effect of Multispecies Probiotic Supplementation on the Efficacy of Rifaximin α Therapy in Patients With Small Intestinal Bacterial Overgrowth (SIBO): a Randomized Placebo-controlled Trial (PHASE4)
- Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia (NA)
- To Evaluate the Effect of Bacillus Subtilis Based Product in Gut Health and Immunomodulatory Effect in Healthy Adults. (NA)
- Oral-Spray Bacillus Spore Probiotics for Periodontal Disease Prevention and Supprotive Treatment in the Elderly (NA)
- The Effect of a Multispecies Probiotics on Autism Symptoms in Children (NA)
- Effects of Multi-strain Bacillus Spore Probiotics on Growth, Digestive Function, and Gut Microbiota in Cesarean-Delivered Neonates (NA)
- Probiotic and Ginger Supplement for Symptoms and Quality of Life in Functional Dyspepsia (SUBTILE) (NA)
- Oral-Spray Bacillus Spore Probiotic in Preventing and Supporting Treatment of Dental Caries in Children (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bacillus subtilis CI brief — competitive landscape report
- Bacillus subtilis updates RSS · CI watch RSS
- DreamTec Research Limited portfolio CI